Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 2025
Postoperative Defect Size as a Criterion for Upstaging High-Risk Cutaneous Squamous Cell Carcinoma Treated With Mohs Micrographic Surgery.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kodumudi Vijay, Rosenthal Amanda, Conde Geena, Juhasz Margit, Gharavi Nima
Аннотация
BACKGROUND: Brigham and Women's Hospital (BWH) criteria classify cutaneous squamous cell carcinoma (cSCC) with a preoperative (clinical) size ≥2 cm as high risk. However, the role of postoperative defect (histologic) size after Mohs micrographic surgery (MMS) in cSCC staging remains unclear.
OBJECTIVE: To compare outcomes of cSCCs treated with MMS that have a clinical size <2 cm but a histologic size ≥2 cm with those clinically ≥2 cm.
METHODS: Data were collected at a tertiary academic center. Patients with cSCC were followed for at least 33 months postoperatively. Recurrence, nodal involvement, metastasis, and disease-specific mortality were collectively analyzed as poor outcomes using multivariable logistic regression.
RESULTS: Among 517 cSCCs, 216 were clinically ≥2 cm, and 301 were histologically ≥2 cm. Univariate analysis showed no significant differences between histologically ≥2 cm and clinically ≥2 cm cSCCs in recurrence or lymph node spread, although histologically ≥2 cm cSCCs were less frequently associated with disease-specific death ( p = .010) and metastasis ( p = .042). Multivariable logistic regression demonstrated that tumors histologically ≥2 cm did not have a significant difference in poor outcomes compared to those clinically ≥2 cm (OR [95% CI] = 0.37 [0.15-1.39]).
CONCLUSION: Postoperative defect size after MMS is a valid parameter for cSCC upstaging using BWH criteria.
OBJECTIVE: To compare outcomes of cSCCs treated with MMS that have a clinical size <2 cm but a histologic size ≥2 cm with those clinically ≥2 cm.
METHODS: Data were collected at a tertiary academic center. Patients with cSCC were followed for at least 33 months postoperatively. Recurrence, nodal involvement, metastasis, and disease-specific mortality were collectively analyzed as poor outcomes using multivariable logistic regression.
RESULTS: Among 517 cSCCs, 216 were clinically ≥2 cm, and 301 were histologically ≥2 cm. Univariate analysis showed no significant differences between histologically ≥2 cm and clinically ≥2 cm cSCCs in recurrence or lymph node spread, although histologically ≥2 cm cSCCs were less frequently associated with disease-specific death ( p = .010) and metastasis ( p = .042). Multivariable logistic regression demonstrated that tumors histologically ≥2 cm did not have a significant difference in poor outcomes compared to those clinically ≥2 cm (OR [95% CI] = 0.37 [0.15-1.39]).
CONCLUSION: Postoperative defect size after MMS is a valid parameter for cSCC upstaging using BWH criteria.